116 related articles for article (PubMed ID: 27456908)
1. [Experience of application of Russian biosimilar of interferon beta-1b for treatment of pediatric multiple sclerosis].
Popova EV; Boyko AN; Bykova OV; Nankina IG; Batysheva TT
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(6):73-75. PubMed ID: 27456908
[TBL] [Abstract][Full Text] [Related]
2. [The first experience of the use the Russian Β-interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis].
Popova EV; Boĭko AN; Davydovskaia MV; Demina TL; Kukel' TM; Lashch NIu; Popova NF; Khachanova NV; Shchur SG; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(10 Pt 2):93-6. PubMed ID: 24300821
[TBL] [Abstract][Full Text] [Related]
3. [Biosimilar of interferon-beta 1b in the treatment of multiple sclerosis and the own experience in the use of ronbetal].
Khabirov FA; Babicheva NN; Khaĭbullin TI; Aver'ianova LA; Granatov EV; Akhmedova GM
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(9 Pt 2):113-22. PubMed ID: 23235429
[TBL] [Abstract][Full Text] [Related]
4. Current perspectives on interferon Beta-1b for the treatment of multiple sclerosis.
Marziniak M; Meuth S
Adv Ther; 2014 Sep; 31(9):915-31. PubMed ID: 25182864
[TBL] [Abstract][Full Text] [Related]
5. [The results of an open comparative retrospective trial of the course of multiple sclerosis during treatment with infibeta and other interferon-beta bioanalogues and glatiramer acetate].
Khabirov FA; Khaybullin TI; Granatov EV; Shakirzianova SR; Babicheva NN; Kochergina OS; Rakhmatullina EF; Akhmedova GM; Averyanova LA; Yakupov MA; Sabirov ZF
Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(3):18-26. PubMed ID: 29652301
[TBL] [Abstract][Full Text] [Related]
6. [Results of a comparative clinical trial of the Russian Β - interferon-1b bioanalogue (infibeta)].
Popova EV; Boĭko AN; Vasil'ev AV; Davydovskaia MV; Zavalishin IA; Kotov SV; Krotenkova MV; Khachanova NV; Sharanova SN; Shchur SG; Iakushina TI
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(5):56-61. PubMed ID: 22951783
[TBL] [Abstract][Full Text] [Related]
7. Interferon beta-1b-induced postmenopausal bleeding in a patient with multiple sclerosis.
Perlman B; Heller D; Cracchiolo B
Climacteric; 2016 Dec; 19(6):599-600. PubMed ID: 27749097
[TBL] [Abstract][Full Text] [Related]
8. [Experience of using genfaxon for treating patients with relapsing-remitting multiple sclerosis in the Russian Federation].
Bakhtiiarova KZ; Bragina OV; Vlasov IaV; Greshnova IV; Evdoshenko EP; Ivanishenkova EI; Kairbekova EI; Karnaukhova EN; Korotkevich NA; Leliukhina AV; Protasov IS; Rybina EV; Sazhnev AI; Skoromets AA; Soldatova OA; Trinitatskiĭ IuV; Fedianin AS; Chelnokova SN; Shabanova VD; Sharipova RR; Shchegol'kova EA; Iampol'skaia-Gosteva IA
Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(8):39-45. PubMed ID: 25345629
[TBL] [Abstract][Full Text] [Related]
9. A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.
Kuhle J; Hardmeier M; Disanto G; Gugleta K; Ecsedi M; Lienert C; Amato MP; Baum K; Buttmann M; Bayas A; Brassat D; Brochet B; Confavreux C; Edan G; Färkkilä M; Fredrikson S; Frontoni M; D'Hooghe M; Hutchinson M; De Keyser J; Kieseier BC; Kümpfel T; Rio J; Polman C; Roullet E; Stolz C; Vass K; Wandinger KP; Kappos L;
Mult Scler; 2016 Apr; 22(4):533-43. PubMed ID: 26362898
[TBL] [Abstract][Full Text] [Related]
10. [The results of an open prospective study of β-interferon biosimilars (an Yaroslavl' cohort)].
Kasatkin DS; Spirin NN; Boiko AN; Stepanov IO; Spirina NN; Baranova NS
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(2 Pt 2):68-73. PubMed ID: 27070364
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Serological Biomarkers of Treatment's Response in Multiple Sclerosis Patients Treated Continuously with Interferonβ-1b for More than a Decade.
Bărcuţean LI; Romaniuc A; Maier S; Bajko Z; Moţăţăianu A; Adina H; Simu I; Andone S; Bălaşa R
CNS Neurol Disord Drug Targets; 2018; 17(10):780-792. PubMed ID: 30221605
[TBL] [Abstract][Full Text] [Related]
12. [The use of beta-interferon-1b in children and adolescents with multiple sclerosis].
Bykova OV; Kuzenkova LM; Maslova OI
Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(9):29-33. PubMed ID: 17069059
[TBL] [Abstract][Full Text] [Related]
13. [Cost-effectiveness analysis of interferon beta-1b as treatment for patients with clinically isolated syndrome suggestive of multiple sclerosis in Spain].
Piñol C
Neurologia; 2016 May; 31(4):247-54. PubMed ID: 25976942
[TBL] [Abstract][Full Text] [Related]
14. The impact of betaplus program on patient treatment satisfaction with interferon beta-1b in multiple sclerosis: Multicentric cross-sectional survey in the western Balkan countries.
Drulovic J; Cukic M; Grgic S; Dincic E; Raicevic R; Nadj C; Toncev G; Vojinovic S; Mesaros S; Kisic Tepavcevic D; Dujmovic I; Tadic D; Miletic-Drakulic S; Dackovic J; Kostic S; Erakovic J; Sakalas L; Savic D; Suknjaja V; Martinovic V; Maric G; Pekmezovic T
Mult Scler Relat Disord; 2017 Jan; 11():56-61. PubMed ID: 28104258
[TBL] [Abstract][Full Text] [Related]
15. Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.
Fitzgerald KC; Munger KL; Köchert K; Arnason BG; Comi G; Cook S; Goodin DS; Filippi M; Hartung HP; Jeffery DR; O'Connor P; Suarez G; Sandbrink R; Kappos L; Pohl C; Ascherio A
JAMA Neurol; 2015 Dec; 72(12):1458-65. PubMed ID: 26458124
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis.
Banwell B; Reder AT; Krupp L; Tenembaum S; Eraksoy M; Alexey B; Pohl D; Freedman M; Schelensky L; Antonijevic I
Neurology; 2006 Feb; 66(4):472-6. PubMed ID: 16505297
[TBL] [Abstract][Full Text] [Related]
17. Liposarcoma concurrence in a multiple sclerosis patient treated with interferon-beta 1b.
Bosnjak Pasic M; Hajnsek S; Panajatovic M; Vidrih B; Bohacek I; Miskov S
J Neurol Sci; 2016 Apr; 363():145-6. PubMed ID: 27000240
[No Abstract] [Full Text] [Related]
18. [Assessment of the high cost drug program on an example of the interferon treatment of multiple sclerosis].
Vlasov IaV; Dolgikh GT; Dolgilh TA; Kurapov MA; Nilov AI; Tarasova SV; Churakov MV; Khivintseva EV
Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(2 Pt 2):66-73. PubMed ID: 23528597
[TBL] [Abstract][Full Text] [Related]
19. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
Kappos L; Freedman MS; Polman CH; Edan G; Hartung HP; Miller DH; Montalbán X; Barkhof F; Radü EW; Metzig C; Bauer L; Lanius V; Sandbrink R; Pohl C;
Lancet Neurol; 2009 Nov; 8(11):987-97. PubMed ID: 19748319
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous necrotic lesion: A wonderful delay adverse effect of interferon beta-1b injection for multiple sclerosis treatment.
Mozafari N; Saffaei A; Alizadeh M; Shabani M
J Cosmet Dermatol; 2020 Apr; 19(4):951-953. PubMed ID: 31436377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
